Covidien Plans Spin-off of Pharmaceuticals Business
Covidien plc, a leading global provider of healthcare products, recently announced it plans to spin off its pharmaceuticals business into a stand-alone public company. Covidien’s pharmaceuticals business is one of the world’s largest producers of bulk acetaminophen, the largest
In addition, Covidien’s pharmaceuticals business is one of the world’s leading suppliers of generators used to produce technetium-99m, a critical diagnostic medical isotope. It also is the only manufacturer that offers a fully integrated system of diagnostic contrast media in prefilled syringes and injectors.
“We’ve evaluated whether to separate these businesses for several years, due to the major differences between the medical products and pharmaceutical industries. We believe that now is the right time to do so because we have significantly improved the operations, performance, and pipeline of our pharmaceuticals business,” said José E. Almeida, President and CEO. “While both businesses hold industry-leading positions, they have distinctly different business models, sales channels, customers, capital requirements, and talent bases. In addition, their respective innovation pipelines differ substantially in length, regulatory approval requirements, possible risks, and potential returns. This transaction, if completed, would give both businesses greater flexibility to focus on and pursue their respective growth strategies, while potentially providing shareholders with greater value over the longer term.”
If a spin-off is executed, the resulting Covidien medical products business would have annual sales of approximately $9.6 billion (based on 2011 reported sales), about evenly split between the
Covidien’s pharmaceuticals business currently generates approximately $2 billion in annual sales, with about two-thirds derived from the
Total Page Views: 1147
